Related Experiment Video

Updated: Feb 3, 2026

Complementation of Splicing Activity by a Galectin-3 - U1 snRNP Complex on Beads
08:48

Complementation of Splicing Activity by a Galectin-3 - U1 snRNP Complex on Beads

Published on: December 9, 2020

2.5K

The role of galectin-3 in heart failure and cardiovascular disease

Xiao Zhong1, Xiaoqian Qian2, Guangping Chen3

  • 1Cardiovascular Center, The Fourth Affiliated Hospital, Harbin Medical University, Harbin, China.

Clinical and Experimental Pharmacology & Physiology
|October 30, 2018
PubMed

Insights

Galectin-3 significantly impacts heart failure progression and cardiovascular disease outcomes. Inhibiting this protein may offer new diagnostic and therapeutic strategies for heart conditions.

Area of Science:

  • Biochemistry
  • Cardiology
  • Molecular Biology

Background:

  • Galectin-3, a β-galactoside-binding lectin, is increasingly recognized for its role in cardiovascular disease.
  • It is implicated in the progression of heart failure (HF) and associated with adverse outcomes in cardiovascular patients.

Purpose of the Study:

  • To review current research on galectin-3's function in cardiovascular fibrosis within heart failure.
  • To explore galectin-3's potential utility in diagnosing, assessing risk, and treating cardiovascular diseases.

Main Methods:

  • Literature review of recent scientific progress.
  • Analysis of studies investigating galectin-3's molecular mechanisms in cardiovascular contexts.

Main Results:

  • Galectin-3 inhibition (genetic or pharmacological) mitigates myocardial inflammation.
  • Inhibition reduces collagen production, attenuates cardiac remodeling, and improves cardiac function.
  • Galectin-3 plays a regulatory role in cardiovascular fibrosis in HF.

Conclusions:

  • Galectin-3 is a key mediator in heart failure progression and cardiovascular fibrosis.
  • Targeting galectin-3 presents potential for novel diagnostic and therapeutic interventions in cardiovascular disease management.

Keywords:
aldosteroneangiotenin IIcardiovascular diseasefibrosisgalectin-3

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
573
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971